FDA Raises Concerns About Patanase Inactive Ingredient
This article was originally published in The Pink Sheet Daily
Executive Summary
Alcon is testing a modified formulation of the olopatadine nasal spray, which is awaiting approval for treatment of seasonal allergic rhinitis.
You may also be interested in...
Alcon Could Re-File Patanase Nasal Spray NDA By End Of 2007
Olopatadine reformulation will require additional preclinical testing, firm says.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.